Pancreatic Cancer Immunotherapy: Why It Fails and How China Is Fighting Back (2026)
Pancreatic cancer remains one of the most lethal malignancies worldwide, with a 5-year survival rate below 10%. Immunotherapy — the breakthrough that transformed treatment for melanoma, lung cancer, and other tumors — has struggled to gain traction in pancreatic ductal adenocarcinoma (PDAC). But a wave of new research from Chinese oncology centers is changing the picture.
This review, originally published in China Cancer (2026, Vol 35, Issue 4), summarizes the clinical landscape, resistance mechanisms, and emerging strategies that may finally unlock immunotherapy’s potential for pancreatic cancer patients.
Why Immunotherapy Fails in Pancreatic Cancer
The “Cold Tumor” Problem
Pancreatic tumors are often called “cold” because they actively suppress the immune system. Multiple layers of defense make it extremely difficult for immune cells to recognize and attack cancer:
Low Immunogenicity
- Low tumor mutational burden (TMB): Fewer mutations mean fewer neoantigens for T cells to recognize.
- Defective antigen presentation: Dendritic cells are impaired, and MHC-I expression on tumor cells is downregulated.
- Inhibitory molecule overexpression: PD-L1, CD47, and galectin-9 actively shut down T-cell activation.
The Physical Barrier
The pancreatic tumor microenvironment (TME) is dominated by a dense desmoplastic stroma — a thick fibrotic matrix produced by cancer-associated fibroblasts (CAFs) and pancreatic stellate cells (PSCs). This stroma:
- Collapses tumor blood vessels, limiting drug delivery
- Prevents infiltration of CD8+ T cells and NK cells
- Creates a physical shield around the tumor
Immunosuppressive Cell Populations
The TME is flooded with cells that actively suppress anti-tumor immunity:
- Increased: M2-type tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs)
- Decreased: Effector CD8+/CD4+ T cells, NK cells, dendritic cells
Soluble Inhibitory Factors
A network of cytokines and chemokines — including TGF-β, SDF-1, IDO, IL-6, IL-10, IL-23, CXCL12, and CCL2 — maintains immunosuppression and recruits additional inhibitory cells to the tumor site.
Current Checkpoint Inhibitors: Limited Impact
Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 or CTLA-4 have shown limited efficacy as monotherapy in pancreatic cancer:
| Trial | Treatment | Result |
|---|---|---|
| KEYNOTE-158 | Pembrolizumab | ORR 18.2% only in MSI-H/dMMR subgroup; <12% in all others |
| KN046 Phase III | Anti-PD-L1/CTLA-4 bispecific | Phase III trial was negative |
The problem: MSI-H and TMB-High status — the biomarkers that predict ICI response — are rare in PDAC, occurring in less than 2% and 1.3% of patients, respectively.
Bottom line: Monotherapy with checkpoint inhibitors is insufficient for most pancreatic cancer patients. Combination and novel strategies are essential.
Combination Strategies: The Most Advanced Approaches
ICIs + Chemotherapy
Combining checkpoint inhibitors with chemotherapy is the most mature strategy, with several promising trials:
PRINCE Trial (2022 ASCO)
- Nivolumab + chemotherapy vs. historical chemotherapy control
- 1-year overall survival: 57.7% vs. 35% — a significant improvement
CISPD3 Trial (Phase III)
- Sintilimab + chemotherapy did not improve progression-free or overall survival
- But doubled the objective response rate (50% vs. 23.9%)
Retrospective Study (57 patients)
- PD-1 inhibitor + chemotherapy showed significantly better outcomes:
- Median PFS: 7.3 vs. 5.8 months
- Median OS: 12.0 vs. 10.2 months
- ORR: 42.9% vs. 17.2%
Pembrolizumab + Chemotherapy (Phase Ib/II)
- Small cohort achieved 100% disease control rate
- Median PFS: 9.1 months, Median OS: 15.0 months
ICIs + Targeted Therapy + Chemotherapy
The NASCA Regimen (Camrelizumab + Sintilimab + Chemotherapy) has emerged as a particularly promising combination:
- Phase Ib/II data (2023/2025 ASCO): ORR 55.0%, median PFS 8.8 months
- vs. AG chemotherapy alone: ORR 23.1%, median PFS 5.8 months
- Especially effective in patients with liver metastases (ORR 90%)
- Phase Ib/II randomized trial (2025 ASCO): ORR 51.1% (p=0.010), median PFS 7.9 months (p=0.045)
Other Notable Combinations:
- Sintilimab + Anlotinib + Chemotherapy: ORR 50.0%, median PFS 8.8 months, median OS 13.7 months (Phase II)
- TQB2868 (PD-1/TGF-β bispecific) + Anlotinib + Chemotherapy: ORR 63.9%, 6-month PFS rate 86% (Phase II, 2025 ASCO)
Emerging Strategies to Break Through Immune Tolerance
Tumor Vaccines
Personalized mRNA Vaccines represent one of the most exciting frontiers:
- Cevumeran + Atezolizumab + Chemotherapy (Phase I): Generated strong, durable neoantigen-specific T-cell responses in 50% of patients. Responders had significantly prolonged recurrence-free survival. T-cell memory persisted for years.
- Multiple trials are ongoing, with results expected in 2026–2027.
Cellular Therapies
CAR-T Cell Therapy targeting mesothelin, Claudin18.2, and other antigens is being explored in early-phase trials. Challenges remain in overcoming the immunosuppressive TME, but combination approaches with ICIs and vaccines may enhance efficacy.
Novel Targets
Researchers are exploring new ways to reprogram the TME:
- TGF-β pathway blockade to reduce fibrosis and immunosuppression
- IDO inhibitors to restore T-cell function
- CD47/SIRPα blockade to enhance macrophage-mediated phagocytosis
- CXCR4/CXCL12 axis targeting to improve immune cell infiltration
What This Means for Patients
If you or a loved one is facing pancreatic cancer, here’s what to consider:
- MSI-H/dMMR testing is essential — if your tumor is MSI-H, checkpoint inhibitors may be highly effective
- Combination therapies are improving outcomes — ask about clinical trials combining ICIs with chemotherapy or targeted therapy
- China is a leading center for pancreatic cancer clinical trials — many of the most promising combination regimens are being developed at Chinese cancer centers
- Personalized mRNA vaccines are in clinical trials and may become available in the coming years
Treatment Centers in China
Several Chinese cancer centers are at the forefront of pancreatic cancer immunotherapy research:
- Zhejiang Cancer Hospital — leading research on combination immunotherapy regimens
- Fudan University Shanghai Cancer Center — clinical trials for novel checkpoint inhibitor combinations
- Ruijin Hospital, Shanghai — pioneering work on pancreatic cancer vaccines and cellular therapies
Key Takeaways
- Pancreatic cancer’s “cold” tumor microenvironment makes immunotherapy challenging but not impossible
- Checkpoint inhibitors alone are insufficient — combination strategies are showing real promise
- Chinese oncology researchers are developing innovative combinations (NASCA regimen, TQB2868-based therapies) with response rates exceeding 50%
- Personalized mRNA vaccines represent the next frontier, with early-phase trials showing durable immune responses
- Clinical trial access in China offers international patients access to cutting-edge treatments
Adapted from: Zheng WY, Zhou SR, Ying JE. Pancreatic Cancer Immunotherapy: Clinical Landscape, Resistance Mechanisms, and Emerging Strategies. China Cancer. 2026;35(4):323-332. Funded by National Key R&D Program of China (2025ZD0552300).
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified oncologist to discuss treatment options appropriate for your specific situation. Clinical trial participation should be discussed with your healthcare team.
Interested in pancreatic cancer treatment options in China? Contact our medical tourism team or explore our clinical trials database for available studies.